Клиномир в тестовом запуске. Кто с нами с первых дней, получит отметку «С первых дней» в профиле и первым увидит новые возможности сайта.

Зарегистрироваться
Завершено Фаза II Россия

Ambrisentan

An Open-label, Long Term Extension Study for Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years Who Have Participated in AMB112529 and in Whom Continued Treatment With Ambrisentan is Desired

Номер протокола114588
ФазаФаза II
Участников по плану — во всех странах исследования38
Сроки21.06.2011 — 09.06.2022
Начало: 21 июня 2011Окончание: 9 июня 2022
Плановый срок исследования истёк

Постоянная ссылка: https://clinomir.ru/trials/nct/NCT01342952/

Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда

Простыми словами

Словарь терминов
  • Фаза II — препарат уже прошёл первую проверку безопасности. Проверяют, действует ли он при этом заболевании, и уточняют дозу.
  • Исследование завершено, новых участников не набирают.
  • Возраст участников: 8–18 лет. Остальные условия — в блоке «Кто может участвовать».
  • По плану участвуют 38 чел. во всех странах исследования.
  • Плановая дата окончания (06.2022) уже прошла.

Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.

Кто может участвовать

Возраст8–18 лет
ПолЛюбой
Здоровые добровольцынет
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 9 · невключение: 7

Критерии включения

  • Have participated in and complied, to the best of their ability, with the protocol for AMB112529 and have met one of the following:
  • Completed the Week 24 visit in AMB112529;
  • Required additional targeted treatment for PAH due to inadequate response to the current treatment or worsening of their clinical condition prior to week 24 in AMB112529;
  • Required reduction in dose of baseline targeted treatment for PAH after ambrisentan was added to the treatment regimen;
  • In the opinion of the investigator, continued treatment with ambrisentan is warranted.
  • A female is eligible to participate in this study, as assessed by the investigator, if she is of:
  • Non-childbearing potential (i.e., physiologically incapable of becoming pregnant); or,
  • Child-bearing potential - has a negative pregnancy test and is not lactating and, if sexually active, agrees to continue to use 2 reliable methods of contraception until study completion and for at least 30 days following the last dose of study drug (reliable methods of contraception are listed in Appendix 2).
  • Subject or subject's legal guardian is able and willing to give written informed consent. As part of the consent, female subjects of childbearing potential will be informed of the risk of teratogenicity and will need to be counselled in a developmentally appropriate manner on the importance of pregnancy prevention; and male subjects will need to be informed of potential risk of testicular tubular atrophy and aspermia.

Критерии невключения

  • Subjects who were withdrawn from ambrisentan in Study AMB112529;
  • Subjects who did not comply with the protocol in Study AMB112529;
  • Female subjects who are pregnant or breastfeeding;
  • Subjects with severe renal impairment (estimated creatinine clearance <30 mL/min assessed within the previous 45 days) at the point of transition from Study AMB112529 into this study;
  • Subject with clinically significant fluid retention in the opinion of the investigator;
  • Subject with clinically significant anaemia in the opinion of the investigator;
  • Subjects who are to enter another clinical trial or be treated with another investigational product after exiting Study AMB112529.

Источник: ClinicalTrials.gov, NCT01342952 · запись обновлена в реестре 30 декабря 2022.

Дизайн и результаты

ДизайнОткрытое (без ослепления), одна группа; цель — лечение
Включено участников (факт, все страны)38
Что измеряют — первичные конечные точки (10), вторичных — 9
  • Number of Participants With Non-serious Treatment-emergent Adverse Events (Non-STEAEs) and Serious Treatment-emergent Adverse Events (STEAEs) — Up to 10 years and 11 months
  • Change From Baseline in Liver Function Parameters: Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Total Bilirubin — Baseline (Day 1) and up to 10 years and 11 months
  • Change From Baseline in Chemistry Parameters: Calcium, Chloride, Carbon Dioxide (CO2) Content, Glucose, Potassium, Magnesium, Sodium, Phosphorus Inorganic, Blood Urea Nitrogen (BUN) — Baseline (Day 1) and up to 10 years and 11 months
  • Change From Baseline in Chemistry Parameters: Alkaline Phosphatase (ALP), Creatine Kinase (CK), Lactate Dehydrogenase (LDH) — Baseline (Day 1) and up to 10 years and 11 months
  • Change From Baseline in Chemistry Parameters: Creatinine, Uric Acid — Baseline (Day 1) and up to 10 years and 11 months
  • Change From Baseline in Chemistry Parameters: Albumin, Total Protein — Baseline (Day 1) and up to 10 years and 11 months
  • Change From Baseline in Hematology Parameters: Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) — Baseline (Day 1) and up to 10 years and 11 months
  • Change From Baseline in Hematology Parameters: Hematocrit — Baseline (Day 1) and up to 10 years and 11 months
  • Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, White Blood Cells (WBC), Platelet Count — Baseline (Day 1) and up to 10 years and 11 months
  • Change From Baseline in Hematology Parameter: Mean Corpuscle Hemoglobin — Baseline (Day 1) and up to 10 years and 11 months

Цель исследования

An open label, long term extension to Study AMB112529. All subjects may remain in the extension study for a minimum of six months. Beyond the six month period, subjects may continue in the extension study until one of the following conditions is met:

the subject turns 18 years of age (when the subject can receive marketed product) the product is approved and available for use in the subject's age group, development for use in the paediatric population is discontinued. the subject decides he/she no longer wants to participate in the study, the investigator considers it is in the best interest of the subject to discontinue ambrisentan (e.g. for safety reasons).

The primary objective is the long-term safety and tolerability of ambrisentan in the paediatric PAH population. Secondary objectives are all cause mortality and change from baseline in Study AMB112529 on efficacy parameters.

Где проходит

0 центров

Центры в реестре не указаны.

Откуда эта информация

  • ClinicalTrials.gov (U.S. National Library of Medicine) · NCT01342952 Официальный реестр (США) · загружено 9 ноября 2026
    Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор

Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.

Изменения не сохранены

На этой странице есть несохранённые изменения. Если уйти со страницы, они пропадут.